Reversible Pulpitis
Conditions
Keywords
Permanent teeth, Complete pulpotomy, Simvastatin -alpha tricalcium phosphate, Mineral Trioxide Aggregate
Brief summary
The study will compare the outcome of complete pulpotomy in mature permanent mandibular molars with deep carious lesions by using Mineral Trioxide Aggregate and Simvastatin -alpha tricalcium phosphate as medicament agent
Detailed description
After a thorough history, clinical and radiographic examination with all eligibility confirmation, written informed consent will be taken from the patient after explaining the procedure, its associated risks and benefits. Clinical diagnosis of reversible pulpitis will be established. Complete pulpotomy will be done in both groups. Mineral Trioxide Aggregate and Simvastatin -alpha tricalcium phosphate will be used as pulpotomy agents. Pain analysis will be carried out preoperatively and postoperatively at every 6 hours for 1 day and then every 24 hours till 7 days after the intervention. All the subjects will be followed up for evaluation of clinical and radiographic success at 3, 6 months and 1 year.
Interventions
Inflammed coronal pulp tissue will be removed till the canal orifices and mineral trioxide aggregate placed over the amputated pulp stump.
Inflammed coronal pulp tissue will be removed till the canal orifices and Simvastatin -alpha tricalcium phosphate placed over the amputated pulp stump.
Sponsors
Study design
Masking description
Double
Eligibility
Inclusion criteria
1. Patient willing to participate in the study. 2. Age group of 15 to 40 years 3. Mature permanent mandibular molars with reversible pulpitis (positive response on the cold test and early response as compared to the adjacent or contralateral tooth) 4. Teeth exhibiting occlusal pulp exposure from primary dental caries. 5. Absence of periapical lesions assessed by radiographic examination. 6. Tooth demonstrating no mobility or swelling and no tenderness to percussion or palpation
Exclusion criteria
1. Primary teeth. 2. Teeth with irreversible pulpitis (spontaneous pain) or pulp necrosis, chronic periodontitis, cracked tooth, internal or external resorption, calcified canals, associated with sinus tract and furcation or apical radiolucency. 3. Immune-compromised, pregnant and patients with any systemic disorder. 4. Patients taking statin medication. 5. Failure to obtain authorization from the patient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical success | Baseline to 12 months | criteria for successful clinical outcome will be absence of clinical sign and symtoms which include Absence of tenderness to percussion,tooth mobility of grade 1 or less.Absence of associated soft tissue swelling or tenderness to palpation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain analysis | Baseline to 7 days | Assess the incidence and intensity of pain postoperatively at every 6 hours to 1 day till 7d ays using Visual Analogue scale.Pain intensity will be noted as no pain (0-4mm), mild pain (5-44), moderate pain (45-74mm) and severe pain (75-100mm) on the scale of 0-100mm |
| Radiographic success | Baseline to 12 months | Radiographic success will be evaluated by change in periapical index (PAI) scores. PAI score 1: Normal periapical structure PAI score 2: Small changes in bone structure PAI score 3: Changes in bone structure with some mineral loss PAI score 4: Periodontis with well defined radiolucent area PAI score 5: Severe periodontitis with elements indicating expansion of lesion |
Countries
India